Results for tag: "Irritable Bowel Syndrome Diagnostics"

The Irritable Bowel Syndrome (IBS) diagnostics market is a sector within gastroenterology focused on products and services that aid in the detection and management of irritable bowel syndrome, a common disorder affecting the large intestine. Diagnosing IBS is typically based on symptoms and by ruling out other conditions. To do so, healthcare providers use a combination of clinical criteria and tests such as blood tests for celiac disease, lactose intolerance tests, stool tests, and sometimes colonoscopy or abdominal imaging when IBS is suspected to be linked to more severe gastrointestinal diseases. The development of new diagnostic tools, including biomarker tests and non-invasive procedures, is an ongoing endeavor in this market. Enhanced diagnostic accuracy is critical for effective management and treatment of IBS, which can significantly improve patient quality of life. Additionally, the market comprises educational resources and dietary management plans, following the understanding that patient education and lifestyle management play crucial roles in the treatment of IBS symptoms. Prominent companies in the IBS diagnostics market include Abbott Laboratories, which supplies diagnostic assays and equipment; Biomerica Inc., known for its diagnostic test kits; Quest Diagnostics, a provider of diagnostic information services; and Rome Foundation, which offers tools for the diagnosis and treatment of functional gastrointestinal disorders. Other notable players include LabCorp, which offers a range of laboratory tests and Thermo Fisher Scientific, which supplies various medical and laboratory equipment. Show Less Read more